Research Summary

My work focuses on the prevention and treatment of HIV infection.

I have been involved in studies of HIV prevention (specifically, truvada for PrEP) for over 12 years. I was the statistician for the iPrEx trial -- the first trial to report the efficacy of oral PrEP and worked on the drugs approval by the FDA. My current work involves studies of the global scale-up of PrEP, innovative designs/statistical analyses of new PrEP agents, and pharmacologic markers of PrEP exposure.

I also collaborate on studies on the outcomes of HIV treatment in resource limited settings. In these settings many patients are absent from clinics. This data requires handling several statistical issues including clustering, competing risk/multiple outcomes, time-dependent covariates and informative censoring. My colleagues and I have pioneered sampling based approaches to losses to follow-up which have given rigorous information about treatment outcomes.

I also collaborate for groups in neurology, pediatrics, LGBT health and nephrology and teach in my department's MCR and Ph.D. program.

Research Funding

  • September 24, 2018 - August 31, 2022 - Statistical methods for clinical trials of novel PrEP agents , Principal Investigator . Sponsor: NIH/NIAIDS, Sponsor Award ID: R01AI143357
  • January 10, 2016 - December 31, 2017 - Comparison of Pharmacologic Markers of Exposure to HIV Pre-Exposure Prophylaxis , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R03AI122908
  • June 19, 2015 - May 31, 2017 - Chemoprophylaxis for HIV Prevention: Analysis of Bone and Metabolic Effects , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R03AI120819
  • April 1, 2001 - March 31, 2006 - FAILURE TIME METHODS FOR FAMILY DISEASE STUDIES , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01HL065411

Education

University of California, Berkeley, CA, BA, 1988, Statistics
University of Washington, Seattle, WA, PhD, 1993, Biostatistics
Harvard University, Boston, MA, Fellowship, 1995, Biostatistics

Honors & Awards

  • 1988
    W.W. Stout Fellowship, Graduate School, University of Washington
  • 1988 - 1990
    Graduate Fellowship Award, Graduate School, University of Washington
  • 1990 - 1993
    National Research Service Award, National Heart, Lung and Blood Institute
  • 1993
    School of Public Health Outstanding Student Citation for Biostatistics, Univ. of Washington
  • 2007
    TICR Award for Excellence in Teaching

Selected Publications

  1. Nadig N, Bhimraj A, Cawcutt K, Chiotos K, Dzierba AL, Kim AY, Martin GS, Pearson JC, Shumaker AH, Baden LR, Bedimo R, Cheng VC, Chew KW, Daar ES, Glidden DV, Hardy EJ, Johnson S, Li JZ, MacBrayne C, Nakamura MM, Riley L, Shafer RW, Shoham S, Tebas P, Tien PC, Loveless J, Falck-Ytter Y, Morgan RL, Gandhi RT 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept.  View on PubMed
  2. Mugwanya KK, Saina M, Mugo NR, MaWhinney S, Morrow M, Schaafsma TT, Donnell D, Glidden DV, Ngure K, Brown CE, Rechkina EA, Chohan BH, Wu L, Hill E, Koome E, Akelo N, Mbaire S, Morrison SA, Kibatha M, Njeru I, Muriithi M, Coppinger C, Bushman L, Baeten JM, Anderson PL, Women Benchmark Study Team Adherence thresholds for emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis against HIV acquisition in cisgender women: A randomized directly observed dosing study.  View on PubMed
  3. Nadig N, Bhimraj A, Cawcutt K, Chiotos K, Dzierba AL, Kim AY, Martin GS, Pearson JC, Shumaker AH, Baden LR, Bedimo R, Cheng VC, Chew KW, Daar ES, Glidden DV, Hardy EJ, Johnson S, Li JZ, MacBrayne C, Nakamura MM, Riley L, Shafer RW, Shoham S, Tebas P, Tien PC, Loveless J, Falck-Ytter Y, Morgan RL, Gandhi RT 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Infliximab.  View on PubMed
  4. Bhimraj A, Falck-Ytter Y, Baden LR, Bedimo R, Cawcutt K, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Johnson S, Kim AY, Li JZ, MacBrayne C, Martin GS, Nadig N, Nakamura MM, Pearson JC, Riley L, Shafer RW, Shoham S, Shumaker AH, Tebas P, Tien PC, Loveless J, Morgan RL, Gandhi RT 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critica  View on PubMed
  5. Byakwaga H, Semeere A, Laker-Oketta M, Busakhala N, Freeman E, Rotich E, Wenger M, Kadama-Makanga P, Kisuya J, Semakadde M, Mwine B, Kasozi C, Mwebesa B, Maurer T, Glidden DV, Wools-Kaloustian K, Kambugu A, Martin J Survival Following Diagnosis of HIV-Associated Kaposi Sarcoma Among Adults in East Africa in the "Treat-All" Era.  View on PubMed
  6. Gebreegziabher EA, Sié A, Ouattara M, Bountogo M, Coulibaly B, Boudo V, Ouedraogo T, Lebas E, Hu H, Ante-Testard PA, Gregorich SE, O'Brien KS, Hsiang MS, Glidden DV, Arnold BF, Lietman TM, Oldenburg CE Exploring Heterogeneity in Treatment Effects: The Impact and Interaction of Asset-Based Wealth and Mass Azithromycin Distribution on Child Mortality.  View on PubMed
  7. van Zyl GU, Decloedt E, Jennings L, Kellermann T, Motha K, van Schalkwyk M, Schreuder C, Coetzee N, Glidden DV, Orrell C, Gandhi M A real-time urine tenofovir assay improves drug adherence among people with HIV with prior virologic failure in a randomized controlled trial.  View on PubMed
  8. Koenig LR, Raymond EG, Upadhyay UD, Frye LJ, Kaneshiro B, Boraas CM, Oldenburg CE, Glidden DV Effectiveness and safety of medication abortion with vs. without screening ultrasonography or pelvic exam.  View on PubMed
  9. Beavers C, Pau AK, Glidden D, Hyle E, Kuriakose S, Martin SS, McComsey G, Thompson M, Virani S, Baker JV Statin Therapy as Primary Prevention for Persons With HIV: A Synopsis of Recommendations From the U.S. Department of Health and Human Services Antiretroviral Treatment Guidelines Panel.  View on PubMed
  10. Nadig N, Bhimraj A, Cawcutt K, Chiotos K, Dzierba AL, Kim AY, Martin GS, Pearson JC, Shumaker AH, Baden LR, Bedimo R, Cheng VC, Chew KW, Daar ES, Glidden DV, Hardy EJ, Johnson S, Li JZ, MacBrayne C, Nakamura MM, Riley L, Shafer RW, Shoham S, Tebas P, Tien PC, Loveless J, Falck-Ytter Y, Morgan RL, Gandhi RT 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab.  View on PubMed
  11. Buccheri R, Spinelli MA, Heise MJ, Glidden DV, Sassaman K, Martinson T, Schmidt HR, D'Angelo AB, Duncan DT, Horvath KJ, Hirshfield S, Williams RS, Johnson MO, Grov C, Carrico A, Gandhi M Feasibility of Point-of-Care Urine Self-Testing to Measure Tenofovir Adherence and Predict Viral Suppression.  View on PubMed
  12. Moses JS, Pau AK, Kuriakose S, Grandits G, Reilly C, Sherman BT, Chang W, Dai L, Khan MA, Highbarger H, Mannah M, McCullough J, Chorley C, Morlu I, Dorbor J, Bongolee OT, Slewion R, Akpa E, Wilson B, Poole AL, Kopka SL, Miller T, Nuta CJ, Lindan C, Glidden D, Martin JN, Johnson KL, Dewar RL, Wachekwa I, Migueles SA HIV-1 suppression and rare dolutegravir resistance in antiretroviral-experienced people with HIV in Liberia.  View on PubMed
  13. Gebreegziabher EA, Ouattara M, Bountogo M, Coulibaly B, Boudo V, Ouedraogo T, Lebas E, Hu H, O'Brien KS, Hsiang MS, Glidden DV, Arnold BF, Lietman TM, Sié A, Oldenburg CE Indirect Benefits of Seasonal Malaria Chemoprevention for Non-Malarial Pediatric Infections and Routine Antibiotic Use in Real-World Programmatic Settings: A Pre-Post Study Using Positive and Negative Controls.  View on PubMed
  14. Gebreegziabher EA, Ouattara M, Bountogo M, Coulibaly B, Boudo V, Ouedraogo T, Lebas E, Hu H, O'Brien KS, Hsiang MS, Glidden DV, Arnold BF, Lietman TM, Sié A, Oldenburg CE The role of Seasonal Malaria Chemoprevention in the effect of Azithromycin on Child Mortality: A Secondary Analysis of the CHAT Cluster Randomized Clinical Trial.  View on PubMed
  15. Moore M, Glidden D, Anderson P, Hendrix C, Dimitrov D Dosing forgiveness of oral PrEP for cisgender women remains uncertain.  View on PubMed
  16. Chitre S, Barrie MB, Kanu JS, Conteh TS, Bayoh M, Kamara MN, Bangura HF, Lascher JS, Frankfurter R, Goldberg SA, Glidden DV, Kelly JD, Lakoh S, Richardson ET Post-Omicron SARS-CoV-2 antibody prevalence in Sierra Leone: A cross-sectional, nationally representative, follow-up serosurvey.  View on PubMed
  17. Peluso MJ, Sandel DA, Deitchman AN, Kim SJ, Dalhuisen T, Tummala HP, Tibúrcio R, Zemelko L, Borgo GM, Singh SS, Schwartz K, Deswal M, Williams MC, Hoh R, Shimoda M, Narpala S, Serebryannyy L, Khalili M, Vendrame E, SenGupta D, Whitmore LS, Tisoncik-Go J, Gale M, Koup RA, Mullins JI, Felber BK, Pavlakis GN, Reeves JD, Petropoulos CJ, Glidden DV, Spitzer MH, Gama L, Caskey M, Nussenzweig MC, Chew KW, Henrich TJ, Yukl SA, Cohn LB, Deeks SG, Rutishauser RL. Combination immunotherapy induces post-intervention control of HIV. Res Sq. 2025 Mar 19.  View on PubMed
  18. Guan A, Wesson P, Glidden DV, Hamad R, Tan JY, Gomez SL. LGB (lesbian, gay, and bisexual) state policy protections and substance use disparities. Health Aff Sch. 2025 Mar; 3(3):qxaf029.  View on PubMed
  19. Spinelli MA, Heise MJ, Gistand N, Cox C, Grochowski J, Oskarsson J, Glidden DV, Gandhi M. HIV Viral Suppression With Use of Long-Acting Antiretroviral Therapy in People With and Without Initial Viremia. JAMA. 2025 Mar 06.  View on PubMed
  20. Crook S, Rosenbluth G, Glidden DV, Fernandez A, Lee CM, Avina L, Magana L, Washington K, Bardach NS. Variations in digital health literacy for pediatric caregivers of hospitalized children: implications for digital health equity. J Am Med Inform Assoc. 2025 Mar 01; 32(3):572-578.  View on PubMed

Go to UCSF Profiles, powered by CTSI